Copyright
©The Author(s) 2022.
World J Cardiol. Jul 26, 2022; 14(7): 403-410
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.403
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.403
Variable | Absolute number | Percentage |
Age | ||
Minimum | 18 | - |
Median | 52 | - |
Maximum | 79 | - |
Body mass index | ||
Minimum | 14.27 | - |
Median | 27.54 | - |
Maximum | 50.58 | - |
Comorbidities | ||
Hypertension | 56 | 13.75 |
Diabetes | 19 | 4.66 |
Lack of other comorbidities reported | 330 | 81.10 |
Menopausal status | ||
Post-menopausal | 304 | 74.69 |
Pre-menopausal | 103 | 25.31 |
Histological subtypes | ||
Invasive ductal carcinoma | 400 | 98.28 |
Invasive lobular carcinoma | 5 | 1.22 |
Others | 2 | 0.50 |
Clinical stage | ||
I | 36 | 8.86 |
II | 129 | 31.69 |
III | 242 | 59.45 |
Chemotherapy regimen | ||
Anthracycline and taxane based | 381 | 93.61 |
Non-anthracycline based | 26 | 6.39 |
Chemotherapy purpose | ||
Neoadjuvant | 204 | 50.12 |
Adjuvant | 203 | 48.88 |
Adjuvant radiotherapy | ||
Yes | 213 | 52.33 |
No | 194 | 47.67 |
Trastuzumab duration | ||
1 yr | 395 | 97.06 |
Less than 1 yr | 12 | 2.94 |
- Citation: Rala de Paula BH, Costa METF, de Sousa CAM, Bines J. Is there a window of opportunity to optimize trastuzumab cardiac monitoring? World J Cardiol 2022; 14(7): 403-410
- URL: https://www.wjgnet.com/1949-8462/full/v14/i7/403.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i7.403